control group:Docetaxel

5 trials

Sponsors

Shanxi Provincial Hospital of Traditional Chinese Medicine, The Second Hospital of Tianjin Medical University, the First Affiliated Hospital of Anhui Medical University, West China Hospital of Sichuan University

Conditions

Lung cancerMetastatic Castration-resistant Prostate Cancer (mCRPC)lung cancerprostate cancer

Phase 3

Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Active, not recruitingChiCTR2600117391

West China Hospital of Sichuan UniversityMetastatic Castration-resistant Prostate Cancer (mCRPC)

Start: 2026-02-01Updated: 2026-01-27

Phase 4

Clinical Study for Sequential Chemotherapy with Apatinib in Patients with Non-small Cell Lung Cancer

RecruitingITMCTR1900002435

Shanxi Provincial Hospital of Traditional Chinese Medicinelung cancer

Start: 2017-03-01Updated: 2023-02-20

Clinical Study for Sequential Chemotherapy with Apatinib in Patients with Non-small Cell Lung Cancer

RecruitingChiCTR1900024189

Shanxi Provincial Hospital of Traditional Chinese Medicinelung cancer

Start: 2017-03-01Updated: 2019-07-01

Efficacy and safety of docetaxel plus sintilimab or docetaxel alone for second line treatment of advanced non-small cell lung cancer without driven gene mutation

Active, not recruitingChiCTR1900025548

the First Affiliated Hospital of Anhui Medical UniversityLung cancer

Start: 2019-10-01Updated: 2019-09-02

Unknown Phase

Individualized treatment of neuroendocrine castration-resistant prostate cancer based on molecular typing: an open, randomized, controlled trial

Active, not recruitingChiCTR1900024895

The Second Hospital of Tianjin Medical Universityprostate cancer

Start: 2019-09-01Updated: 2019-08-27